Bristol Myers Reports Preliminary KarXT Phase 3 Findings
Open-label ADEPT-1 results showed a mean 12.0-point reduction in hallucination and delusion scores over 12 weeks from a 14.4 baseline. ADEPT-3’s 52-week extension showed a mean 5.1-point reduction from an 8.9 baseline; double-blind data remain blinded.